-
Watson garners 24% increase in Q2 sales
PARSIPPANY, N.J. — Watson Pharmaceuticals had sales of $1.1 billion during second quarter 2011, the generic drug maker said.
In a financial report released Tuesday, Watson said the sales figures for the quarter represented a 24% increase over sales in second quarter 2010. Profit for the quarter was $52.4 million, compared with $70.6 million in second quarter 2010.
“Our record $1 billion in net revenues in the second quarter demonstrates the strength of our combined global generics and global brands strategies,” Watson president and CEO Paul Bisaro said.
-
Lupin seeks to market generic Lo Loestrin Fe
NEW YORK — Generic drug maker Lupin is seeking approval for a generic version of a contraceptive made by Warner Chilcott, according to published reports.
Reuters reported that Lupin had applied for approval of a generic version of Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets), an oral contraceptive.